Datavant vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Datavant is the largest health data ecosystem connecting healthcare organizations through privacy-preserving tokenization that enables real-world data linkage across systems.
About
Datavant is a health data company founded in 2017 that has built the largest real-world health data ecosystem in the United States through its privacy-preserving data tokenization technology. The company's platform enables healthcare organizations including hospitals, insurers, pharmaceutical companies, and research institutions to link patient records across databases without sharing identifying information, using consistent de-identified tokens that allow data to be joined securely. Datavant raised over $600M and expanded significantly through its merger with Ciox Health, combining Datavant's tokenization technology with Ciox's medical record retrieval operations. The company serves life sciences companies that need real-world evidence from claims, EHR, and specialty data sources, payers managing population health programs, and health systems that want to generate revenue from their patient data while maintaining privacy compliance. Datavant's network effect grows as more organizations adopt the tokenization standard, making the ecosystem more valuable for every participant. The platform has become critical infrastructure for real-world evidence generation in pharmaceutical development and health economics research.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.